HBOT Indications: An Overview
Hyperbaric oxygen therapy has evidence across a wide range of medical conditions, though the strength of that evidence varies significantly by indication. Understanding where a given condition sits on the evidence spectrum — from UHMS-approved standard-of-care to research-stage to investigational — is essential for setting realistic expectations and making informed treatment decisions.
Tier 1: UHMS-Approved Indications (Standard of Care)
The Undersea and Hyperbaric Medical Society maintains the authoritative list of 14 approved HBOT indications. These are the conditions for which the clinical evidence base is considered sufficient to recommend HBOT. US Medicare (CMS) reimbursement generally follows this list, and FDA chamber clearances are tied to it. Included indications span emergency care (decompression sickness, carbon monoxide poisoning, gas gangrene), wound care (diabetic foot ulcers, radiation injury, compromised grafts), and specific sensorineural conditions (sudden hearing loss, added 2021).
Tier 2: Research-Stage Indications (Growing Evidence)
Several conditions have substantial research evidence but are not yet UHMS-approved. The most prominent are the neurological applications studied extensively by the Efrati Lab in Tel Aviv: traumatic brain injury, chronic stroke recovery, long COVID, and fibromyalgia. These indications have RCT-level evidence at 2.0 ATA over 40–60 sessions but remain off-label and typically out-of-pocket for US patients.
Tier 3: Investigational Indications (Limited Evidence)
Other conditions — PTSD, autism spectrum disorder, age-related cognitive decline, anti-ageing, sports recovery — have mixed or early-stage evidence. Signal exists in individual trials but RCT replication is inconsistent. These should be considered experimental; marketing claims in this space often exceed the published data.
How HBOT Works Across Indications
Despite the diversity of HBOT indications, several core mechanisms recur. Elevated plasma oxygen delivers oxygen to tissue by diffusion, bypassing compromised vascular supply. HIF-1α stabilisation drives angiogenesis — new capillary formation in previously hypoperfused tissue. Stem cell mobilisation supports tissue repair after approximately 20 sessions. Mitochondrial biogenesis improves cellular energy metabolism. Antimicrobial effects — direct bactericidal activity against anaerobes plus enhanced neutrophil-mediated killing — address infection. Neuroinflammation modulation is central to the neurological indications. These mechanisms explain why a single therapy can address conditions as diverse as diabetic ulcers and traumatic brain injury.
Choosing Where to Pursue HBOT
For UHMS-approved indications, UHMS-accredited hospital hyperbaric facilities are the standard of care, with CMS/Medicare coverage. For off-label indications, options include private hyperbaric clinics (cash-pay), research-affiliated academic centres (clinical trial enrolment), and in some cases home HBOT (soft-shell 1.3 ATA chambers, with the caveat of weaker evidence at this pressure). Always discuss indication, protocol, and expected outcomes with a qualified hyperbaric physician before committing to a course.